Why did Moderna stock drop today? Bullish mRNA projections from rival Pfizer
Maddie Meyer         

ModernaÂ lost 7%Â in Monday trading after rival Pfizer (PFE) issued bullish projections about its mRNA-based vaccine franchise.
Pfizer said it sees a $10Bâ$15B commercial market opportunity for its mRNA vaccines by 2030. Besides its Comirnaty COVID-19 vaccine, other mRNA shots in development are for flu and shingles.
In late-stage development, Moderna (NASDAQ:MRNA) has mRNA vaccines for flu, respiratory syncytial virus (RSV), and cytomegalovirus (CMV).
Read why Seeking Alpha contributor JR Research cut Moderna (MRNA) to hold from speculative buy.